An observational study in Skin Cancer, Skin Diseases and Atopic Dermatitis, sponsored by HJN Sverige AB/Neko Health. Recruiting at 3 sites in Sweden. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-25.
Sponsored by HJN Sverige AB/Neko Health · Observational
Among 19 studies in Skin Neoplasms with a site in Sweden — 10 open to participants now, 10 under way, 1 of them phase 3. Skin Neoplasms · Sweden.
Among the 19 studies in Skin Neoplasms with a site in Sweden, this one is one of 5 that started in 2023, is one of 8 observational ones, and was the 14th registered.
604 studies on the registry are indexed under Skin Neoplasms; 126 are open to participants now.
Browse Skin Neoplasms studies →10 of the 19 studies in Skin Neoplasms with a site in Sweden are open now. Recruiting first, the newest first:
Linkoeping University · Sites in Sweden
Region Skane · Sites in Sweden
Iovance Biotherapeutics, Inc. · Sites in Sweden, United States, Australia and 13 more countries
HJN Sverige AB/Neko Health · Sites in Sweden
Region Skane · Sites in Sweden
A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →
Of the 104 Skin Neoplasms studies recruiting now, 84 (81%) set no upper age limit and 9 (9%) stop at 75 or younger; 15 take children under 18; 25 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 5 started in 2023.
This study's planned enrollment of 8,000 is above the median of 200 across 157 observational studies indexed under Skin Neoplasms.
Median enrollment 402 across the 11 interventional studies, 2,642 across the 8 observational. Of the 8 that completed or were terminated, 4 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 19 have an industry lead sponsor. The 10 most frequent:
HJN Sverige AB/Neko Health is the lead sponsor of 6 studies on the registry; 6 are open to participants now.
HJN Sverige AB/Neko Health has 2 studies filed under Skin Neoplasms — fewer than ten, so there is no comparison to draw.
3 of the studies in Skin Neoplasms with a site in Sweden that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05446155Region SkaneBioMEL- Diagnostic and Prognostic Factors in Melanoma. | 2026-12 |
| NCT04904146Lund University HospitalPredictive and Prognostic Biomarkers in Patients With Mycosis Fungoides and Sézary Syndrome. | 2027-04 |
| NCT06932172Linkoeping UniversityArtificial Intelligent Decision Support for Skin Cancer Diagnostics in Primary Care | 2027-05-31 |
Among the 19 studies in Skin Neoplasms with a site in Sweden, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This clinical trial is about evaluating the suitability of multi-modal imaging technology, which covers virtually the entire body, to evaluate the possibility of screening and early detection of disease.
This clinical investigation aims to evaluate the feasibility of full-body multi-modal imaging for screening, monitoring and diagnostic support purposes in primary care, by assessing accuracy of body measurements and sensitivity and correlation to disease. The performance in detection of skin cancer, peripheral arterial disease, Raynaud's phenomenon and dermatological conditions are within the scope of this investigation.
The multi-modal technology is based on camera systems, which can capture high-resolution 2D and 3D color images (visible spectrum) and thermal images (infrared spectrum). The appearance, shape, color, etc. and topography of lesions is captured by the color 2D camera of the system and can thus be inspected / quantified. Thermal images are used to capture thermal gradients which may be indicative of microcirculatory changes. The 3D camera is used to ensure that 2D color data and thermal data can be geometrically aligned, thus being able to compare characteristics of the two data types from the very same skin segment / lesion. Furthermore, it enables geometrical measurements of the lesions.
The participants mainly consist of a prospective primary care population, that undergo an investigation at a primary care visit. Full-body images (front and back) of all participants are captured during the visit. Participants receive a questionnaire to fill in on-site, where they state whether they have/have had any of the diseases and conditions part of the investigation. In some subjects, body measurements (circumference and distance) will be acquired manually as part of the primary care flow. Repeated yearly measurements may be performed in subjects who are interested.
All patients visiting the clinical sites, seeking care, or as separately invited, are offered to participate in this investigation. This includes sub-groups of patients with suspected skin cancer, acne, rosacea, psoriasis, eczema, PAD and Raynaud's.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study participants mainly consist of a prospective primary care population. All patients visiting the clinical sites, seeking care, or as separately invited, are offered to participate in this investigation. This includes sub-groups of patients with skin cancer and dermatological conditions.
Sensitivity for detection of lesions requiring excision in comparison to visual inspection
Evaluate the sensitivity of detecting lesions that required excision by inspection and labelling of full-body color images acquired by full-body photography. Manual labelling of images acquired by full-body photography will be compared to ocular inspection by doctor on-site, performed as part of a standard primary care flow. An expert reviewer blinded to outcome from ocular inspection will perform the manual labelling of images.
Time frame: Typically same day as enrolment, or if follow-up then 1 year following enrolment.
Difference in body metrics between full-body 3D photography and traditional measurements
Evaluation of the mean difference in estimated body height, body circumference measurements and distance measurements (carotid centre - suprasternal notch, carotid centre - femoral centre and suprasternal notch - symphysis) using 3D images acquired by full-body photography compared to manual measurement using standard tape measures or height measurement tools. Difference is reported in metric units.
Time frame: Typically same day as enrolment, or if follow-up then 1 year following enrolment.
Sensitivity in detection of dermatological conditions with 2D images from full-body photography
Percentage of all dermatological (eczema, psoriasis, rosacea), identified by self-reported diagnosis or by ocular inspection by a healthcare professional, which can be identified by 2D images from full-body photography (remote assessment by a trained healthcare professional, blinded to the outcome). The categories of assessment conclusion may include: 1. Cleared, no presence of specified condition 2. Diagnosed with condition 3. Further diagnostic steps are needed.
Time frame: Typically same day as enrolment, or if follow-up then 1 year following enrolment.
Sensitivity in detection of new or significantly changed lesions, from macroscopic images using 2D and 3D full-body photography.
Sensitivity in detection of whether there are new or changed lesions on the visible parts of the body, based on a set of 2D and 3D images acquired using full-body photography. Expert reviewers with competence in lesion assessment will review images from subjects who have had no changed lesions and those who have had an excised lesion at second visit. . Images from initial and follow-up visit will be compared side-to-side. The expert reviewer will then classify, based on a collation of 2D and 3D images, into categories: 1. Significantly changed lesion 2. New lesion 3. No changed lesion.
Time frame: Typically same day as enrolment, or if follow-up then 1 year following enrolment.
Correlation between thermal gradient in hands and/or feet with diagnosis of peripheral arterial disease or Raynaud's phenomenon
Evaluate correlation between thermal temperature gradient in thermal images acquired using full-body photography and diagnosis of peripheral arterial disease (PAD) and Raynaud's phenomenon. Confirmation of pathology presence is based on self-reported diagnosis from an on-site questionnaire. Alternatively, diagnosis is based on information from the participant's electronic health record if they are seeking care for a condition following their study visit.
Time frame: Typically same day as enrolment, or if follow-up then 1 year following enrolment.
Thermal gradient of inflammatory area compared to surrounding skin to detect presence of psoriasis arthritis
Thermal profile (local gradient / relative temperature difference) related to presence of psoriasis arthritis, determined by self-reported diagnosis and/or diagnosis extracted from electronic health record.
Time frame: Typically same day as enrolment, or if follow-up then 1 year following enrolment.
Association between thermal profile/local gradient and presence of inflammatory skin conditions.
Thermal profile (absolute temperature)/local gradient (relative temperature difference) in relation to presence of inflammatory skin condition determined by self-reported diagnosis, and/or diagnosis extracted from electronic health record.
Time frame: Typically same day as enrolment, or if follow-up then 1 year following enrolment.
Identification of potential cancerous lesions by assessment of thermal profile of suspected lesions
Thermal gradient (relative temperature difference from thermal images between lesion and surrounding tissue) of suspected lesions that have been cleared to lesions determined to be cancerous. Lesions are pre-labelled by expert reviewer with relevant experience.
Time frame: Typically same day as enrolment, or if follow-up then 1 year following enrolment.
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2023 (actual). Primary completion is estimated for Feb 2026, 36 months after the start.
Of 78 observational studies under Skin Neoplasms, half reached primary completion within 72 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 248. This study's planned 36 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
HJN Sverige AB/Neko Health